Juan Carlos Martín

Juan Carlos Martín

Auto-generated profile, based on publicly available information

Juan Carlos Martín

Instituto de Catálisis y Petroleoquímica, CSIC, C/ Marie Curie s/n, Cantoblanco, 28049 Madrid, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2006 in Applied Catalysis B: Environment and Energy
Verified
Journal Article
Closed access
SMS. Mendioroz
S. Mendioroz
AMA.B. Martín-Rojo
A.B. Martín-Rojo
FRF. Rivera
F. Rivera
JMJ.C. Martín
J.C. Martín
ABAna Bahamonde
Ana Bahamonde
MYM. Yates
M. Yates

1 December 2001 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JMJ.C. Martín
J.C. Martín
VSVicente Soriano
Vicente Soriano
IJI. Jiménez-Nácher
I. Jiménez-Nácher
PPPABLO PEREZ-MARTINEZ
PABLO PEREZ-MARTINEZ
JGJ. González-Lahoz
J. González-Lahoz

1 January 2021 in European Journal of Medical Case Reports
Verified
Journal Article
Open access
PIPaula Ibáñez
Paula Ibáñez
ÁIÁngel Manuel Iniesta
Ángel Manuel Iniesta
ÁRÁngel Robles
Ángel Robles
MGMariana Gutiérrez
Mariana Gutiérrez
FBFrancisco Bermúdez
Francisco Bermúdez
JMJuan Carlos Martín
Juan Carlos Martín
Background: In some patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]), an uncontrolled release of inflammatory cytokines is characteristic. COVID-19 and adult-onset Still’s disease (AOSD) have been included by some authors in the “hyperferritinemic syndromes.” Another hyperinflammatory syndrome (with variable features of Kawasaki disease) called multisystem inflammatory syndrome (MIS) has been described in patients who have had SARS-CoV-2 infection. Case Presentation: We present a previously healthy patient who developed hyperinflammatory reaction compatible with MIS; the clinical presentation is additionally compatible with AOSD, complicated with a mild myocarditis. The patient had a positive SARS-CoV-2 serology (immunoglobulins G and immunoglobulins M ), but multiple reverse transcription-polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 on nasopharyngeal swab were negative or indeterminate, so we considered that it is possible that an asymptomatic SARS-CoV-2 infection could have been the trigger for Still’s disease. 24 hours after starting methylprednisolone treatment, the fever was resolved and symptoms improved over the next few days, with persistent arthralgias. Conclusion: Asymptomatic SARS-CoV-2 infection could trigger MIS with AOSD-like features.